Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oritavancin - Melinta Therapeutics

Drug Profile

Oritavancin - Melinta Therapeutics

Alternative Names: KIMYRSA; LY-333328; LY-333328 diphosphate; Nuvocid; ORBACTIV; Oritavancin diphosphate; Ramvocid

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Melinta Therapeutics; Menarini; The Medicines Company
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Bacteraemia
  • No development reported Gram-positive infections
  • Discontinued Anthrax; Clostridium difficile infections

Most Recent Events

  • 15 May 2023 Oritavancin licensed to Xediton Pharmaceuticals in Canada
  • 13 Apr 2023 Phase-II clinical trials in Skin and soft tissue infections (In adolescents, In children, In infants) in Spain, Bulgaria (IV) (EudraCT2022-001297-63)
  • 31 Oct 2022 Melinta Therapeutics plans a phase II trial for Skin and soft tissue infections (In infants, In children, In adolescents) in USA (IV, Infusion, Single) in October 2022 (NCT05599295) (EudraCT2022-001297-63)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top